.jpeg)
2026-06-03 03:11:10
This article provides a detailed analysis of the oral BRAF inhibitor vemurafenib, explaining its mechanism of action against the BRAF V600E mutation, its central role in treating advanced melanoma, its potential in other rare conditions like Erdheim-Chester disease, and outlines its standard usage and key safety considerations.
2026-06-02 06:02:23
Vemurafenib is an oral targeted therapy that selectively inhibits the BRAF V600E mutant protein, offering a revolutionary treatment option for patients with specific types of melanoma and marking the era of "precision medicine" in oncology.
2026-05-29 07:46:00
A comprehensive analysis of the latest clinical data for the highly selective KRAS G12C inhibitor Garsorasib in NSCLC and solid tumors, covering first-line chemotherapy combinations, immunotherapy regimens, brain metastasis efficacy, and resistance management.
2026-05-27 02:05:59
Zongertinib (Hernexeos) gains FDA approval for HER2-mutated NSCLC, offering targeted therapy based on 76% response rate data, transforming treatment landscape.
2026-05-25 04:05:18
Explore the breakthrough of Sotorasib (AMG-510), the first approved KRAS G12C inhibitor. Detailed clinical trial data, dosage guidelines, and global pricing insights for patients in Hong Kong, Macau, and worldwide.
2026-05-22 04:06:55
LONSURF® (Trifluridine/Tipiracil) has become a cornerstone in the later-line treatment of metastatic colorectal cancer. This article explores its origins at Taiho Pharmaceutical, its unique mechanism of action, and the robust global manufacturing network ensuring its quality and availability.
2026-05-21 06:42:31
Eli Lilly announced FDA approval of Inluriyo (Imlunestrant), an oral estrogen receptor antagonist for ER+, HER2- advanced breast cancer with ESR1 mutations post-endocrine therapy progression.
2026-05-20 02:31:44
Explore the medicinal chemistry and clinical profile of Tivozanib. This guide covers its synthetic route, high selectivity for VEGFR, and role in targeted therapy for advanced kidney cancer.
2026-05-20 02:26:46
A comprehensive guide to Trifluridine/Tipiracil (FTD/TPI), an oral chemotherapy for metastatic colorectal and gastric cancers. Learn about safety profiles, bone marrow suppression, and clinical management strategies.
2026-05-19 07:04:42
This article details the medication precautions and risk management strategies for the KRAS G12C targeted inhibitor Adagrasib in women of childbearing age, pregnant and lactating women, elderly patients, and patients with underlying comorbidities.
2026-05-18 04:21:15
Olutasidenib (Rezlidhia) is an oral IDH1 mutation inhibitor developed by Rigel Pharmaceuticals. Approved by the FDA in 2022, it is used for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring IDH1 mutations. With definite efficacy and good tolerability, it provides a precise targeted treatment option for such patients.
2026-05-18 04:06:05
Capmatinib, a highly selective MET inhibitor, demonstrates transformative efficacy in METex14-mutated NSCLC. Pivotal GEOMETRY data show significant tumor shrinkage and survival improvement, particularly in brain metastases. Global accessibility through originator and generic options empowers patients, while ongoing combo therapies and resistance research expand future horizons.
